These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 12515754)
41. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study. Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114 [TBL] [Abstract][Full Text] [Related]
42. Doxazosin Stimulates Galectin-3 Expression and Collagen Synthesis in HL-1 Cardiomyocytes Independent of Protein Kinase C Pathway. Qian X; Li M; Wagner MB; Chen G; Song X Front Pharmacol; 2016; 7():495. PubMed ID: 28066244 [TBL] [Abstract][Full Text] [Related]
43. Maspin sensitizes prostate cancer cells to doxazosin-induced apoptosis. Tahmatzopoulos A; Sheng S; Kyprianou N Oncogene; 2005 Aug; 24(34):5375-83. PubMed ID: 16007219 [TBL] [Abstract][Full Text] [Related]
44. Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Pool JL Am J Cardiol; 1987 May; 59(14):46G-50G. PubMed ID: 2884853 [TBL] [Abstract][Full Text] [Related]
46. ATP-binding cassette transporter A1 gene transcription is downregulated by activator protein 2alpha. Doxazosin inhibits activator protein 2alpha and increases high-density lipoprotein biogenesis independent of alpha1-adrenoceptor blockade. Iwamoto N; Abe-Dohmae S; Ayaori M; Tanaka N; Kusuhara M; Ohsuzu F; Yokoyama S Circ Res; 2007 Jul; 101(2):156-65. PubMed ID: 17556657 [TBL] [Abstract][Full Text] [Related]
47. Mechanism of alpha blockade for blood pressure control. Davey M Am J Cardiol; 1987 May; 59(14):18G-28G. PubMed ID: 2884849 [TBL] [Abstract][Full Text] [Related]
48. Correction of neurovascular deficits in diabetic rats by beta2-adrenoceptor agonist and alpha1-adrenoceptor antagonist treatment: interactions with the nitric oxide system. Cotter MA; Cameron NE Eur J Pharmacol; 1998 Feb; 343(2-3):217-23. PubMed ID: 9570470 [TBL] [Abstract][Full Text] [Related]
49. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417 [TBL] [Abstract][Full Text] [Related]
50. Growth inhibitory effect of doxazosin on prostate and bladder cancer cells. Is the serotonin receptor pathway involved? Siddiqui EJ; Shabbir M; Thompson CS; Mumtaz FH; Mikhailidis DP Anticancer Res; 2005; 25(6B):4281-6. PubMed ID: 16309229 [TBL] [Abstract][Full Text] [Related]
51. Doxazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in mild or moderate hypertension. Young RA; Brogden RN Drugs; 1988 May; 35(5):525-41. PubMed ID: 2899495 [TBL] [Abstract][Full Text] [Related]
52. Doxazosin inhibits human vascular endothelial cell adhesion, migration, and invasion. Keledjian K; Garrison JB; Kyprianou N J Cell Biochem; 2005 Feb; 94(2):374-88. PubMed ID: 15526277 [TBL] [Abstract][Full Text] [Related]
53. alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. Randle LE; Sathish JG; Kitteringham NR; Macdonald I; Williams DP; Park BK Br J Pharmacol; 2008 Feb; 153(4):820-30. PubMed ID: 18071297 [TBL] [Abstract][Full Text] [Related]
54. Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. Vashi V; Chung M; Hilbert J; Lawrence V; Phillips K J Clin Pharmacol; 1998 Nov; 38(11):1072-6. PubMed ID: 9824790 [TBL] [Abstract][Full Text] [Related]